Browse by Medical Category
Support this Center
The Henri and Belinda Termeer Center for Targeted Therapies offers new hope to patients and their families at the Massachusetts General Hospital Cancer Center and beyond, as the center defines the future of cancer therapy.
Led by Keith T. Flaherty, MD, a renowned expert in personalized cancer medicine and melanoma specialist, the Termeer Center offers a comprehensive translational research program to speed the discovery and delivery of new targeted therapies to patients with early and advanced stage cancers.
The Termeer Center brings together cutting-edge research resources and provides a foundation for collaborations among physicians and investigators from a broad spectrum of biomedical disciplines, resulting in a rapidly expanding arsenal of weapons against cancer. Leading specialists from the Cancer Center’s 24 disease centers participate in the Termeer Center by enrolling their patients in its fast-growing portfolio of Phase I, Phase II and Phase III clinical trials.
The cycle of discovery is swift and efficient, with newly identified genetic abnormalities revealing new information about cancer pathways and creating novel investigative possibilities, not only for Mass General researchers but for scientific collaborators around the world. The Termeer Center's goal is to cut the average time for drug development from ten years to five and, with more clinical trials, improve access to therapy for patients. With hundreds of new anti-cancer therapies now in the development pipeline and countless patients waiting for targeted drugs that match their individual tumors, the Termeer Center's work is vital and timely.
The Mass General Cancer Center is a world leader in personalized cancer medicine, the concept of matching molecularly-targeted treatments to specific genetic abnormalities that enable cancer cells in a patient's tumor to thrive. The Cancer Center's proven track record of discovery includes significant breakthroughs in lung cancer, melanoma and breast cancer, among others.
In many ways, the Termeer Center represents a paradigm shift from traditional clinical cancer research. For example, in traditional clinical trials, experimental therapies are tested first in patients who have not responded to standard treatments; with genotype-based targeted therapies, clinical trials can begin at a much earlier stage of the disease process, when the chances of observing benefits for the patient are far greater. Additionally, since various forms of cancer have been found to share common tumor mutations, researchers are learning to apply targeted drugs across multiple tumor types.
The Center for Targeted Therapeutics conducts extensive basic and translational research to accelerate the delivery of new, cutting-edge therapies into the clinical setting. Our current research includes:
Learn more about targeted clinical trials at https://targetedcancercare.massgeneral.org
The bi-annual Termeer Symposium, presented by the Henri and Belinda Termeer Center for Targeted Therapies, features discussions from leading experts on cutting-edge topics in personalized cancer medicine. Learn more here.
Back to Top